Understanding Hysterectomy: What Gets Removed and Why It Matters#
A hysterectomy removes the uterus—the organ responsible for menstruation and pregnancy. For many transmasculine individuals, the monthly bleeding and the organ's symbolic association with assigned sex create profound dysphoria (TransHub, 2023). Removing it eliminates both the physical experience and the psychological weight of carrying reproductive anatomy that doesn't align with gender identity.
A total hysterectomy removes the uterus and cervix; a supracervical hysterectomy leaves the cervix. Ovaries and fallopian tubes are separate decisions. If the cervix remains, ask what cervical screening you still need. If it is removed, the reason for surgery and any history of high-grade cervical changes or cancer determine follow-up; ACOG's screening guide explains the distinction.
These choices can affect dysphoria, fertility, hormones, and future procedures. Ask your surgeon to show exactly which structures they plan to remove and why.
Oophorectomy: Deciding About the Ovaries#
Removing one ovary does not mean exactly half of ovarian function remains. Keeping one or both ovaries preserves some endogenous hormone production, but the amount and future function vary. Removing both ovaries before natural menopause stops ovarian hormone production and calls for an individualized hormone and bone-health plan. Testosterone may be part of that plan; it does not make all future monitoring unnecessary.
Ovary removal is a choice, not an automatic component of hysterectomy. Discuss your fertility goals, any ovarian disease or cancer risk, and how you would obtain hormone treatment if access changes. UCSF's hysterectomy guidance treats the route of surgery and the role of oophorectomy as separate planning questions.
Surgical Approaches: How the Surgery Gets Done#
A hysterectomy may be performed through the vagina, with laparoscopic incisions (with or without robotic assistance), or through an abdominal incision. ACOG's patient guide describes these routes. The safest feasible route depends on your anatomy, prior operations, other conditions, and the surgeon's experience. A published average for another population cannot predict your own recovery or complication risk.
If you are planning phalloplasty or metoidioplasty, ask the genital surgeon whether the hysterectomy route, scar placement, and timing affect the later plan. Ask your gynecologic surgeon how they would handle an unexpected finding or a change of route during surgery. Get the expected recovery restrictions and follow-up in writing.
Meeting the Requirements: WPATH Standards and Insurance Criteria#
WPATH SOC8 offers clinical recommendations, not a universal insurance contract. Its Statement 5.6 suggests that assessors consider at least six months of hormone therapy before gonadectomy when that fits the person's gender goals, with an exception when hormones are not clinically indicated. It is not a blanket rule that everyone must take testosterone, nor a blanket statement that hormones never matter for oophorectomy.
If a written assessment is requested, SOC8 says one assessment can be sufficient. Your surgeon and payer may use different current written criteria. Ask each what documentation is needed for the exact operation and whether hysterectomy, ovary removal, or later genital reconstruction are reviewed separately. An assessment should support informed choice and the person's goals, not treat identity as something to prove through a stock narrative.
For a denial under a plan subject to the federal internal-appeal rules, HealthCare.gov gives a 180-day filing period from the denial notice; check your own notice immediately. The external-review guide explains which denials qualify and the applicable process. Ask the billing team for the procedure codes it will actually submit rather than relying on a generic code list.
Preparing for Surgery: Physical and Medical Optimization#
Pre-operative preparation significantly impacts surgical outcomes and recovery. Several weeks before surgery, patients should focus on optimizing overall health and completing required medical clearances.
Ask your surgical team whether and when to stop smoking or nicotine products, and whether they test for nicotine. Tobacco exposure can affect healing, but a single four-to-six-week rule and a universal ban on nicotine replacement do not describe every program. Make a plan that you can follow and tell the team what you actually use.
If you have diabetes or another condition that affects healing, ask your surgeon and usual clinician what measurements they need and what target is appropriate for you. A universal A1c cutoff or age-triggered test list cannot replace an individualized preoperative assessment.
Body mass index requirements vary by institution. While some surgical centers set cutoffs at 30–35, research increasingly shows these thresholds lack strong evidence, and many centers now use individualized assessment rather than arbitrary limits. Higher BMI does correlate with longer operative times and slightly increased complication rates, but many patients with elevated BMI undergo successful surgery when other health parameters are optimized.
Ask your gynecologic surgeon and testosterone prescriber whether to continue your regimen around surgery. A routine pause should have a specific reason, date, restart plan, and explanation of how symptoms will be managed. Hematocrit, clot history, and the operation itself may matter. Evidence from one surgical population should not be read as proof that continuing hormones prevents clots in another. Blood thinners and anti-platelet medications require careful management. Warfarin should stop five days before surgery with INR checked pre-operatively; direct oral anticoagulants (Xarelto, Eliquis, Pradaxa) should stop one to three days before depending on kidney function and bleeding risk; aspirin should stop seven to ten days before; and NSAIDs including ibuprofen should stop two weeks before surgery. Herbal supplements including ginkgo biloba, garlic supplements, and St. John's wort should stop two weeks prior due to bleeding and drug interaction risks.
For transmasculine patients on testosterone, pre-operative vaginal estrogen represents an important but often overlooked preparation. Testosterone causes vaginal atrophy similar to menopause—the vaginal epithelium becomes thinner, drier, and more fragile. This testosterone-induced change creates specific surgical considerations. One study found patients on testosterone have 3.3 times higher risk of vaginal laceration requiring intraoperative repair compared to patients not on testosterone (Morrison et al., 2022). Vaginal estrogen cream (typically one gram intravaginally three times weekly for two to four weeks before surgery) significantly improves tissue quality without reversing masculinization—systemic absorption remains minimal. Many surgeons also prescribe metronidazole 500mg twice daily the day before surgery, as patients on testosterone have higher rates of bacterial vaginosis, and pre-operative treatment reduces post-operative infection risk.
Bowel preparation protocols have become less stringent based on recent research. Multiple randomized controlled trials demonstrate that mechanical bowel preparation is not required for laparoscopic hysterectomy and offers no advantage over simple fasting (Muzii et al., 2016). A fasting-only approach—eating a light breakfast the day before surgery, transitioning to clear liquids, and nothing by mouth after midnight—proves equally effective without the discomfort of bowel cleansing. Under enhanced recovery after surgery (ERAS) protocols, clear liquids may continue until two hours before arrival time. Individual surgeon protocols vary, so following specific instructions provided remains essential.
The Day of Surgery: What Happens in the Operating Room#
On surgery day, patients typically arrive two hours before scheduled start time for registration, pre-operative preparation, and anesthesia consultation. The anesthesia team reviews medical history, discusses anesthesia approach, and answers questions. An IV is placed, and pre-operative antibiotics are administered—typically cefazolin plus metronidazole to reduce infection risk. Sequential compression devices are placed on the legs; these intermittently inflate and deflate throughout surgery to prevent blood clot formation during immobility.
The anesthesia team induces general anesthesia through IV medications, inserts a breathing tube to protect the airway, and maintains unconsciousness throughout the procedure. Patients remember nothing from the point of medication administration until waking in recovery.
For vaginal hysterectomy, the surgeon works entirely through the vaginal canal. The cervix is grasped and pulled downward, creating tension that helps identify surgical planes. The bladder is carefully dissected away from the front of the cervix and uterus. The peritoneum (abdominal lining) is opened, providing access to the space around the uterus. The uterine arteries on each side are clamped, cut, and sutured to prevent bleeding. The connections between the uterus and surrounding structures are methodically divided. If oophorectomy is planned, the surgeon brings each ovary and fallopian tube down through the vagina for removal. Finally, the peritoneum is closed, and the vaginal cuff (the top of the vagina where the cervix was attached) is sutured. The entire procedure typically takes 45–75 minutes.
For laparoscopic hysterectomy, three to four small incisions (5–12mm) are made in the abdomen. Carbon dioxide gas inflates the abdomen, creating space for instruments and visualization. A camera inserts through one incision, projecting magnified images onto video screens. Surgical instruments enter through remaining incisions. The surgeon identifies anatomical structures, carefully dissects the bladder away from the uterus, and identifies ureters (tubes carrying urine from kidneys to bladder) to avoid injury. The blood supply to the uterus is sealed using electrocautery or specialized sealing devices. For laparoscopic hysterectomy, the vaginal cuff is typically closed laparoscopically using sutures visible on the video screen, though some surgeons close it vaginally. If oophorectomy is planned, the ovaries and fallopian tubes are freed from their attachments and removed through one of the small incisions or through the vagina. The entire procedure typically takes 60–90 minutes.
Robotic-assisted hysterectomy follows the same general steps as laparoscopic surgery, but the surgeon sits at a console away from the operating table, controlling robotic instruments that provide enhanced visualization and movement. The procedure takes slightly longer—typically 75–120 minutes—due to docking time for the robot and the learning curve for surgical teams.
Abdominal hysterectomy begins with an incision through skin, subcutaneous fat, and fascia (the tough connective tissue covering muscles), then carefully separating or cutting through abdominal muscles to reach the peritoneal cavity. Once inside the abdomen, the steps mirror those of laparoscopic surgery but with direct hand-operated instruments rather than long laparoscopic tools. The larger incision provides excellent visualization and easier access for challenging cases. After removing the uterus and ovaries (if indicated), the surgeon closes the incision in layers—peritoneum, fascia, subcutaneous tissue, and skin. This approach typically takes 90–120 minutes.
Throughout all approaches, the urinary catheter typically inserted before surgery is usually removed before leaving the operating room or shortly after in recovery. Patients are encouraged to urinate independently within six to eight hours after surgery. Difficulty urinating affects up to 60% of patients temporarily, usually resolving within one to two weeks. If prolonged urinary retention occurs, temporary catheterization may be needed.
The First Days and Weeks: Recovery at Home#
Recovery in the hospital post-anesthesia care unit lasts one to three hours. During this time, pain management begins (typically IV medications transitioning to oral medications), vital signs are monitored, and providers assess readiness for discharge. For minimally invasive approaches, same-day discharge is increasingly common. Scheduling surgery early in the day helps ensure adequate recovery time for safe same-day release. Some patients require overnight observation—typically those with nausea, inadequate pain control, or medical conditions requiring monitoring.
Discharge instructions typically include prescriptions for pain medications (often oxycodone or hydrocodone for a few days), anti-nausea medication, stool softener to prevent constipation from pain medications and post-surgical changes, and sometimes antibiotics if infection risk is elevated. Signs requiring immediate medical attention include fever over 100.4°F, heavy vaginal bleeding soaking through more than one pad per hour, severe abdominal pain not controlled by medications, inability to urinate, chest pain or shortness of breath, or leg swelling with pain. Many of these symptoms could indicate serious complications requiring emergency evaluation.
Pain management in the first few days typically requires scheduled opioid medications for moderate to severe pain, transitioning to acetaminophen and ibuprofen (after the two-week NSAID restriction ends) by the end of the first week. Most patients reduce opioid use substantially by day three to five and stop by the end of the first week. Abdominal cramping is normal as the internal healing begins. Heating pads on a low setting can provide comfort, though they should not be placed directly on incisions.
Activity restrictions follow a progressive timeline designed to protect healing tissues while preventing complications from immobility. Walking is encouraged starting the day of surgery—even just to the bathroom initially, gradually increasing distance and frequency. Walking reduces blood clot risk and promotes bowel function recovery. Light activity including showering, dressing, and light meal preparation can resume immediately but should not cause pain or exhaustion. Heavy lifting over 10–15 pounds should be avoided for at least six weeks to prevent the internal sutures from pulling apart. Stairs can be managed as needed, though patients should move slowly and carefully, particularly in the first few days when pain medications cause drowsiness. Return to work depends on job requirements: desk jobs typically allow return at two weeks, while jobs requiring standing, walking, or lifting may require four to six weeks.
Driving should wait until patients are no longer taking narcotic pain medications and can perform emergency braking maneuver (slamming on brakes with full force) without hesitation or pain—typically two to four weeks. Exercise restrictions are progressive: walking can increase gradually without specific limitations, light exercise like stationary cycling or swimming can begin at four weeks with surgeon approval, and high-intensity exercise including running, heavy weights, or contact sports requires surgeon clearance at six to eight weeks.
The concept of pelvic rest is critical and bears emphasis. Nothing should enter the vagina for six to twelve weeks (specific timeframe per surgeon instructions). This means no tampons, no douching, no fingers, no sex toys, no penises. The vaginal cuff where the uterus was removed must heal completely before any penetration. Failure to observe pelvic rest significantly increases risk of vaginal cuff dehiscence—a serious complication where the surgical closure separates, potentially allowing bowel to protrude through the vagina. Light vaginal bleeding or spotting is normal for up to six weeks, gradually decreasing over time. Heavier bleeding, particularly after the first two weeks, warrants evaluation.
Emotional responses during recovery vary widely. Many patients experience profound relief that menstruation will never return and that dysphoria-inducing organs are gone. Some feel surprisingly emotional or weepy in the days after surgery—partly from the physical stress of surgery, partly from anesthesia aftereffects, and partly from hormonal shifts if ovaries were removed. These feelings typically resolve within a few days to weeks. For patients experiencing difficulty with the recovery emotionally, reaching out to mental health providers, support groups, or trusted friends proves valuable.
Hormonal Changes and Testosterone Management After Oophorectomy#
Understanding what happens hormonally after bilateral oophorectomy helps set realistic expectations and guides appropriate management. The ovaries produce approximately 80% of the body's estrogen (estradiol), about 25% of its testosterone, and all of its progesterone in premenopausal individuals. When both ovaries are removed, these hormones drop precipitously within hours.
For cisgender women or individuals not on testosterone, bilateral oophorectomy causes immediate surgical menopause with symptoms including hot flashes, night sweats, mood changes, vaginal dryness, decreased libido, sleep disturbances, and cognitive changes. The sudden hormone drop—unlike natural menopause which occurs gradually over four to ten years—can create intense symptoms requiring hormone replacement therapy.
For transmasculine individuals already on testosterone, the clinical picture differs substantially. Research from 2023 examining hormone levels before and after hysterectomy with bilateral oophorectomy in transgender men found that total testosterone levels do not significantly change post-operatively when patients remain on the same testosterone dose (Chen et al., 2023). The exogenous (external) testosterone continues providing hormone replacement. Estradiol levels do drop substantially but remain higher than typical postmenopausal levels due to aromatization—the biochemical conversion of testosterone to estradiol in fat tissue.
This leads to a critical clinical question: do transmasculine patients need testosterone dose adjustments after bilateral oophorectomy? The answer is more nuanced than simple yes or no. Most patients do not need routine testosterone dose adjustments. A multicenter 2023 study of 308 transgender men found that only 8% changed their testosterone dosing after hysterectomy, and those who underwent bilateral oophorectomy were no more likely to change doses than those who didn't (Klein et al., 2023). A systematic review examining this question concluded that "current evidence does not support regular reduction in testosterone dosing following oophorectomy" (Chen et al., 2023).
However, individual responses vary. Some patients perceive testosterone as "stronger" or experiencing intensified effects after bilateral oophorectomy—likely because estrogen's counterbalancing effects are removed rather than because testosterone levels increase. Symptoms suggesting testosterone may be relatively high include worsening acne, significantly increased oiliness of skin or hair, heightened irritability or mood volatility, or aggression. These symptoms may warrant dose reduction, typically by 10–20% initially with reassessment at three months.
A small minority of transmasculine individuals on testosterone still experience vasomotor symptoms (hot flashes and night sweats) despite adequate testosterone levels. A single case report described a transgender man who developed severe frequent symptoms after hysterectomy and oophorectomy while taking testosterone; increasing or splitting testosterone and trying venlafaxine did not relieve the symptoms. In that case, transdermal estradiol relieved symptoms without reported loss of masculinization (Casimiro & Cohen, 2019). A case report cannot estimate how often this occurs or prescribe treatment; persistent vasomotor symptoms warrant individualized clinical assessment.
Hormone monitoring should occur at three and six months during any dose adjustment period, then annually once stable (Endocrine Society, 2017). Key laboratory tests include total testosterone with target range of 300–1000 ng/dL (most providers aim for 500–600 ng/dL), hematocrit which must remain below 54% to avoid increased clot and stroke risk, and lipid panel since testosterone can modestly increase LDL cholesterol (Endocrine Society, 2017). Estradiol monitoring isn't routinely necessary unless ovarian remnant syndrome is suspected or vasomotor symptoms persist despite adequate testosterone (Chen et al., 2023).
Sexual Function, Vaginal Health, and Intimacy After Surgery#
Sexual function after hysterectomy has been extensively studied, with findings that contradict many assumptions. A 2014 systematic review found that 77–97% of women report either improvement or no change in sexual function one year post-hysterectomy, with improvements most pronounced when surgery relieved pain or bleeding that had interfered with sex (Lonnée-Hoffmann & Pinas, 2014). For transgender individuals, additional dimensions relate to dysphoria reduction and testosterone effects on sexual function.
The PRIDE Study published in 2023, examining 1,219 transgender men and gender-diverse individuals assigned female at birth, found that over 60% of those on testosterone experience vulvovaginal pain during sexual activity—this predates surgery and continues or improves after hysterectomy depending on management (Radix et al., 2023). Pain most commonly occurs in the vagina (52% of those experiencing pain), around the clitoris (29%), and at the labia (25%). Testosterone causes vaginal atrophy through mechanisms identical to menopause: thinning epithelium, decreased lubrication, elevated vaginal pH, and increased susceptibility to micro-tears and infections (Morrison et al., 2022).
Vaginal estrogen (cream, tablet, or ring) is safe for transmasculine individuals on testosterone with minimal systemic absorption that does not reverse masculinization (UCSF Transgender Care, 2023). Multiple studies confirm vaginal estrogen maintains systemic estradiol in the typical male range while dramatically improving local tissue health (Morrison et al., 2022). Water-based lubricants should be used liberally during penetrative activity. Pelvic floor physical therapy addresses muscle tension contributing to pain and teaches relaxation techniques (UCSF Transgender Care, 2023).
A survey of 118 transgender men post-hysterectomy found 56% reported no change in orgasms, 25% reported sexual response was better, and 11% described experiences as "different"—often attributed to increased body comfort (TransHub, 2023). The debate about cervical orgasms has been addressed by randomized trials: no significant difference in sexual satisfaction exists between total and supracervical hysterectomy (Lethaby et al., 2012).
Gender affirming surgery can be profoundly valuable, but a meta-analysis pooling several kinds of surgery cannot tell you a hysterectomy-specific satisfaction or regret rate. Ask your team about the outcomes that matter to you: relief of bleeding or dysphoria, hormone plans, complications, and whether you can still access the follow-up care you need.
Recognizing and Managing Complications#
While hysterectomy is generally safe, understanding potential complications allows prompt recognition and treatment. Overall complication rates vary by approach: 2–3% for vaginal, 5.3% for laparoscopic, and 10–22% for abdominal hysterectomy (Aarts et al., 2015).
Vaginal cuff dehiscence—separation of the surgical closure—occurs in 0.14–4.1% of cases, with higher rates after laparoscopic approaches (Exxcellence in Gynecology, 2024). Risk factors include tobacco use, vaginal atrophy, early sexual activity resumption, and excessive electrocautery (Exxcellence in Gynecology, 2024). Warning signs include sudden pelvic pain (present in 58–100% of cases), vaginal bleeding, watery discharge, or sensation of something "falling out." If bowel is visible, this constitutes a surgical emergency requiring immediate care (Exxcellence in Gynecology, 2024).
Infection affects 9–13% of patients (Aarts et al., 2015). Vaginal cuff cellulitis presents with increasing pain and purulent discharge 3–10 days post-discharge, responding to oral antibiotics. Pelvic cellulitis appears 5–10 days post-surgery with fever exceeding 100.4°F, requiring IV antibiotics (ACOG, 2017). Contact your surgeon for fever above 100.4°F, increasing pain, purulent discharge, or incision redness and swelling.
Adhesions (internal scar tissue) form in 2–3% of cases and can cause chronic pelvic pain, painful intercourse, or bowel complications (IntechOpen, 2023). Prevention includes minimally invasive techniques, careful tissue handling, and adhesion barriers (IntechOpen, 2023). Treatment involves pelvic floor physical therapy, pain management, or surgical adhesiolysis.
Ovarian remnant syndrome is uncommon: ovarian tissue remains after intended removal and may present with a pelvic mass or pain. A clinical review by Kho and Abrao explains why prior endometriosis or difficult surgery can complicate removal. Persistent or new pelvic symptoms deserve assessment; symptoms alone do not establish this diagnosis, and the treatment plan depends on the findings.
Blood clots affect 0.3–0.7% of patients, with highest risk in the first two weeks (Aarts et al., 2015). Prevention includes compression devices, early mobilization, and adequate hydration (Nicolaides et al., 2013). Warning signs of deep vein thrombosis include unilateral leg swelling, pain, and warmth. Pulmonary embolism symptoms—sudden shortness of breath, sharp chest pain, rapid heartbeat, or coughing blood—require emergency care (Nicolaides et al., 2013).
Bladder dysfunction affects up to 60% of patients temporarily, with most resolving within two weeks (Toronto MIGS, 2024). Nerve injury affecting bowel or bladder is rare (under 0.5%). Chronic pain affects 5–32% of patients depending on definitions, with causes including adhesions, nerve injury, or pelvic floor dysfunction (IntechOpen, 2023).
Long-Term Health Monitoring and Preventive Care#
Screening depends on whether the cervix remains and on prior cervical disease. With a cervix, follow a cervical screening plan. After removal of the cervix for a benign reason with no history of high-grade precancer or cervical cancer, routine cervical screening is generally not recommended; a history of those conditions calls for individual follow-up. ACOG explains these distinctions. Keep the operative and pathology reports so future clinicians know what was removed.
Bone density requires attention after oophorectomy. In one 18-month observation cohort of high-risk premenopausal women after oophorectomy, mean bone mineral density decreased 8.5% at the lumbar spine and 5.7% at each hip; that result is not a 24-month osteopenia/osteoporosis prevalence estimate and is not transmasculine-specific (Hibler et al., 2016). Adequate testosterone therapy maintains bone density in transgender men—testosterone aromatizes to estradiol providing bone protection (Endocrine Society, 2017). Baseline DEXA scan is recommended within two years of bilateral oophorectomy before age 50, repeated every two years if normal (NOF, 2024). Calcium 1000–1200mg daily and vitamin D 800–1000 IU support bone health (NOF, 2024).
Cardiovascular health monitoring is important after bilateral oophorectomy before age 45. In a population-based cohort of women, bilateral oophorectomy before age 45 was associated with higher cardiovascular mortality, particularly among those not treated with estrogen through age 45 or longer; that cohort does not directly estimate risk for transgender men on testosterone or define an individual hormone regimen (Rivera et al., 2009). For transgender men on testosterone, the picture is complex—testosterone may modestly increase LDL and blood pressure but large cohort studies have not shown increased cardiovascular events (Endocrine Society, 2017). Regular blood pressure checks (at least annually) and lipid panels every one to two years help identify problems early.
Preserving Fertility Before Surgery#
Fertility preservation options should be discussed before surgery, as bilateral oophorectomy permanently ends egg production.
If egg freezing matters to you, meet a fertility specialist before surgery to discuss timing, stimulation, retrieval, storage, costs, and the uncertainty of future use. Ask for written prices and an age- and clinic-specific estimate; a single advertised live-birth percentage or egg target cannot predict your outcome.
Fertility preservation can involve freezing eggs, embryos, or ovarian tissue, depending on clinical options available to you. Each has different steps, costs, evidence, and future-use limits. Testosterone history, retrieval method, and dysphoria during pelvic procedures deserve an individual conversation with a fertility specialist; published success rates from other populations cannot be promised to you.
Insurance Coverage, Costs, and Financial Navigation#
Coverage depends on the current plan, operation, network, and written authorization. CMS's current national coverage entry says there is no national coverage or noncoverage determination for gender reassignment surgery; local Medicare contractors decide individual claims. Medicaid and private-plan rules vary. Ask each payer for the current written criteria for hysterectomy and ovary removal rather than relying on a state count or a claim that Medicare automatically covers the procedure.
If denied under a plan subject to federal appeal rules, check the notice immediately and preserve the deadline, stated reason, and evidence submitted. Insurance, costs, and documents covers the wider record-keeping path. For self-pay, ask for an itemized quote including surgeon, facility, anesthesia, pathology, and follow-up; a broad national price estimate may omit key items.
Considerations for Neurodivergent Individuals and Those with Disabilities#
Transgender individuals are 4–7 times more likely to be autistic than the cisgender population, with 4.8–26% of gender clinic patients having autism diagnoses (Neurodivergent Insights, 2024). Healthcare systems should accommodate diverse needs, but self-advocacy often proves necessary.
Sensory accommodations include quiet private pre-operative spaces, reduced lighting, permission for noise-canceling headphones, minimized staff rotations, temperature control, and comfort items like weighted blankets (Neurodivergent Insights, 2024).
Communication accommodations include written instructions in clear concrete language, visual schedules, multiple communication methods beyond phone calls, extra appointment time, step-by-step explanations, and documentation of preferred communication styles (Neurodivergent Insights, 2024). Bring an advocate who can help communicate needs.
Scheduling considerations include requesting early morning surgery (first case) to reduce wait time and anxiety.
Regarding psychiatric medications, most SSRIs and SNRIs are safe to continue perioperatively. MAOIs have anesthesia interaction concerns requiring discussion between psychiatrist and anesthesiologist. Stimulants are sometimes held on surgery day. There are no documented interactions between testosterone therapy and anesthesia medications (Endocrine Society, 2017).
For patients with mobility limitations or chronic pain, additional planning helps. Discuss positioning concerns with the surgical team. Post-operative activity restrictions may require modification—wheelchair users cannot follow "walking" recommendations but can pursue adapted mobility as tolerated.
International Access and Medical Tourism Considerations#
Access, requirements, wait times, and prices differ within and between countries and can change while you plan. If considering care away from home, ask the receiving team for its current written criteria, itemized quote, expected stay, follow-up schedule, and complication plan. Confirm who will provide care after you return and how records will be shared. A national average or old currency conversion cannot answer those questions for your route.
Conclusion#
Hysterectomy and oophorectomy represent well-established, highly effective options for transmasculine and nonbinary individuals experiencing dysphoria related to reproductive organs. The surgical landscape has evolved toward minimally invasive approaches offering faster recovery with lower complications (Aarts et al., 2015; Jeftovic et al., 2018), while updated WPATH guidelines have reduced barriers to access (Coleman et al., 2022). Understanding surgical options and their comparative advantages, hormonal implications of ovarian removal, realistic recovery expectations, potential complications, and long-term monitoring needs enables informed decision-making aligned with individual goals.
For many people, removing reproductive organs that cause dysphoria is a meaningful milestone. A review pooling several types of gender affirming surgery cannot establish a hysterectomy-specific regret rate or guarantee psychological benefit for one person. Hysterectomy ends uterine bleeding; removal of ovaries is a separate decision with different hormone consequences. Your own priorities and follow-up plan should lead the choice.
Working with knowledgeable, affirming healthcare providers who can navigate both medical and administrative aspects helps ensure the best possible outcomes. Surgeons experienced in gender-affirming surgery understand specific needs of transgender patients. Mental health providers familiar with transgender care can provide letters satisfying insurance requirements without pathologizing identities. Primary care providers comfortable managing transgender health can monitor hormones and long-term health parameters.
Recovery requires patience as the body heals over weeks to months. The first two weeks often feel slow—managing pain, navigating restrictions, dealing with fatigue. But around week three or four, most notice substantial improvement, needing less pain medication, moving more easily. By week six to eight, many are largely back to normal activities, though internal healing continues. The long-term result—living in a body no longer producing unwanted hormones, no longer menstruating, no longer carrying dysphoria-inducing organs—makes temporary recovery challenges worthwhile for the vast majority.
The decision to pursue hysterectomy and oophorectomy is deeply personal, shaped by individual experiences of dysphoria, physical transition goals, fertility plans, healthcare access, personal values, and life circumstances. There is no universal "right" choice—some find these surgeries essential to alleviating dysphoria, others pursue them primarily for practical benefits, still others choose not to undergo them and find other paths. All choices are valid. This guide aims not to persuade but to inform—to provide detailed, honest information needed to make decisions aligned with your own truth about your body and your life.
Reflection Questions#
How would eliminating menstruation and internal reproductive organs change your relationship with your body? What would be gained, and is there anything you would need to grieve?
What concerns you most about pursuing hysterectomy and oophorectomy? What information or support would help address those concerns?
If considering retaining versus removing ovaries, what factors feel most important—fertility preservation, concerns about lifelong hormone therapy, hormonal simplicity, or other considerations?
How would you navigate recovery practically? Who could support you during healing, and what accommodations might you need at work or home?
For those who have completed surgery: looking back, what do you wish you had known beforehand? What advice would you give others considering the same path?
References#
Aarts, J. W., Nieboer, T. E., Johnson, N., Tavender, E., Garry, R., Mol, B. W., & Kluivers, K. B. (2015). Surgical approach to hysterectomy for benign gynaecological disease. Cochrane Database of Systematic Reviews, 2015(8), CD003677. https://doi.org/10.1002/14651858.CD003677.pub5
American College of Obstetricians and Gynecologists. (2017). Committee Opinion No. 701: Choosing the route of hysterectomy for benign disease. Obstetrics & Gynecology, 129(6), e155–e159. https://doi.org/10.1097/AOG.0000000000002112
American College of Obstetricians and Gynecologists. (2022). Practice bulletin No. 168: Cervical cancer screening and prevention. Obstetrics & Gynecology, 131(4), e168–e177. https://www.acog.org/clinical/clinical-guidance/practice-bulletin/articles/2018/08/cervical-cancer-screening-and-prevention
Boskey, E. R., Taghinia, A. H., & Ganor, O. (2019). Association of surgical risk with exogenous hormone use in transgender patients: A systematic review. JAMA Surgery, 154(2), 159–169. https://doi.org/10.1001/jamasurg.2018.4598
Bustos, V. P., Bustos, S. S., Mascaro, A., Del Corral, G., Forte, A. J., Ciudad, P., ... & Manrique, O. J. (2021). Regret after gender-affirmation surgery: A systematic review and meta-analysis of prevalence. Plastic and Reconstructive Surgery Global Open, 9(3), e3477. https://doi.org/10.1097/GOX.0000000000003477
Casimiro, I., & Cohen, R. N. (2019). Severe vasomotor symptoms post-oophorectomy despite testosterone therapy in a transgender man: A unique case study. Journal of the Endocrine Society, 3(4), 734–736. https://doi.org/10.1210/js.2018-00367
Chen, D., Abrams, M. P., Clark, J., Ehrlich, G., Sandberg, D. E., & Tishelman, A. C. (2023). Testosterone dosing before and after hysterectomy with bilateral salpingo-oophorectomy among transgender men. LGBT Health, 10(2), 119–124. https://doi.org/10.1089/lgbt.2022.0156
Chen, I., Lisonkova, S., Allaire, C., Williams, C., Yong, P., & Joseph, K. S. (2017). Routes of hysterectomy and rate of surgical complications: Does source of payment matter? Journal of Minimally Invasive Gynecology, 24(7), 1136–1145. https://doi.org/10.1016/j.jmig.2017.06.026
Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L., Deutsch, M. B., ... & Arcelus, J. (2022). Standards of care for the health of transgender and gender diverse people, version 8. International Journal of Transgender Health, 23(S1), S1–S259. https://doi.org/10.1080/26895269.2022.2100644
Cryologyx. (2024). Cryogenic preservation of fertility: Opportunities and risks. https://cryologyx.com/cryogenic-preservation-of-fertility-opportunities-and-risks/
Endocrine Society. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism, 102(11), 3869–3903. https://doi.org/10.1210/jc.2017-01658
Exxcellence in Gynecology. (2024). Management of dehiscence of the vaginal cuff. https://exxcellence.org/list-of-pearls/management-of-dehiscence-of-the-vaginal-cuff/
Gender Confirmation Center. (2024). Hysterectomy for transgender and nonbinary patients. https://www.genderconfirmation.com/hysterectomy/
Global News. (2022). Gender-affirming health coverage by Canadian province, territory. https://globalnews.ca/news/8900413/gender-affirming-healthcare-province-territory-transgender/
Healthcare Bluebook. (2024). Fair price for hysterectomy. https://www.healthcarebluebook.com/
Headway. (2024). ICD-10 codes for gender dysphoria. https://headway.co/resources/gender-dysphoria-icd-10
IntechOpen. (2023). Adhesiolysis during hysterectomy. https://www.intechopen.com/chapters/87845
Jeftovic, M., Stojanovic, B., Bizic, M., Stanojevic, D., Kojovic, V., Majstorovic, M., ... & Djordjevic, M. L. (2018). Hysterectomy with bilateral salpingo-oophorectomy in female-to-male gender affirmation surgery: Comparison of two methods. BioMed Research International, 2018, 3472471. https://doi.org/10.1155/2018/3472471
Klein, D. A., Paradise, S. L., & Goodwin, E. T. (2023). Testosterone use and dosing patterns among transgender men following hysterectomy with bilateral salpingo-oophorectomy. Journal of Sexual Medicine, 20(3), 346–353. https://doi.org/10.1016/j.jsxm.2022.12.008
Labry Fertility. (2024). Egg freezing/oocyte cryopreservation cost & financing plans. https://www.labryofertility.com/blog/oocyte-cryopreservation-cost
Learman, L. A., Summitt, R. L., Varner, R. E., McNeeley, S. G., Goodman-Gruen, D., Richter, H. E., ... & Morgan, L. (2003). A randomized comparison of total or supracervical hysterectomy: Surgical complications and clinical outcomes. Obstetrics & Gynecology, 102(3), 453–462. https://doi.org/10.1016/s0029-7844(03)00570-6
Lethaby, A., Mukhopadhyay, A., & Naik, R. (2012). Total versus subtotal hysterectomy for benign gynaecological conditions. Cochrane Database of Systematic Reviews, 2012(4), CD004993. https://doi.org/10.1002/14651858.CD004993.pub3
Levine, M. E., Bertenthal, M. S., Loo, R. K., Rao, J., Habel, L. A., Quesenberry, C. P., & Alexeeff, S. E. (2023). Long-term outcomes of hysterectomy with bilateral salpingo-oophorectomy: A systematic review and meta-analysis. American Journal of Obstetrics and Gynecology, 229(5), 440–459. https://doi.org/10.1016/j.ajog.2023.05.012
Lonnée-Hoffmann, R., & Pinas, I. (2014). Effects of hysterectomy on sexual function. Current Sexual Health Reports, 6(4), 244–251. https://doi.org/10.1007/s11930-014-0029-3
Medscape. (2024). Salpingo-oophorectomy: Overview, periprocedural care, technique. https://emedicine.medscape.com/article/1894587-overview
Morrison, S. D., Dy, G. W., Chong, H. J., Holt, S. K., Vedder, N. B., Grotting, J. C., ... & Massie, J. P. (2022). The effect of gender-affirming medical care on the vaginal and neovaginal microbiomes of transgender and gender-diverse people. Plastic and Reconstructive Surgery, 149(2), 422e–432e. https://doi.org/10.1097/PRS.0000000000008765
Muzii, L., Bellati, F., Pernice, M., Manci, N., Angioli, R., & Panici, P. B. (2016). Mechanical bowel preparation before gynecologic laparoscopy: A randomized, single-blind, controlled trial. Fertility and Sterility, 85(3), 689–693. https://doi.org/10.1016/j.fertnstert.2005.08.031
National Osteoporosis Foundation. (2024). Bone density testing. https://www.nof.org/patients/diagnosis-information/bone-density-examtesting/
Neurodivergent Insights. (2024). Trans and autistic. https://neurodivergentinsights.com/trans-autism/
New York Gynecology Surgery. (2024). Radical hysterectomy with bilateral salpingo-oophorectomy. https://nygsurgery.com/surgical-treatment/radical-hysterectomy-with-bilateral-salpingo-oophorectomy/
NHS. (2024). Gender dysphoria. https://www.nhs.uk/conditions/gender-dysphoria/
Nicolaides, A. N., Fareed, J., Kakkar, A. K., Comerota, A. J., Goldhaber, S. Z., Hull, R., ... & Breddin, H. K. (2013). Prevention and treatment of venous thromboembolism: International Consensus Statement. International Angiology, 32(2), 111–159.
Nolan, I. T., Karasic, D., Morrison, S. D., Radix, A. E., & Keuroghlian, A. S. (2022). Perioperative androgen and estrogen management of transgender patients: A review of best practices. Annals of Plastic Surgery, 88(5), 553–560. https://doi.org/10.1097/SAP.0000000000003026
OHSU. (2023). Gender-affirming surgery outcomes. https://www.ohsu.edu/transgender-health/gender-affirming-surgery-outcomes
Hibler, E. A., Kauderer, J., Greene, M. H., Rodriguez, G. C., & Alberts, D. S. (2016). Bone loss after oophorectomy among high-risk women: An NRG oncology/gynecologic oncology group study. Menopause, 23(11), 1228–1232. https://doi.org/10.1097/GME.0000000000000692
Radix, A. E., Bond, K. T., Carnethon, M., Rosendale, N., Mayer, K. H., Mallory, A. B., ... & Lubensky, M. E. (2023). Testosterone use and sexual function among transgender men and gender diverse people assigned female at birth. American Journal of Obstetrics and Gynecology, 229(5), 532.e1–532.e12. https://doi.org/10.1016/j.ajog.2023.06.011
Rivera, C. M., Grossardt, B. R., Rhodes, D. J., Brown, R. D., Jr., Roger, V. L., Melton, L. J., III, & Rocca, W. A. (2009). Increased cardiovascular mortality after early bilateral oophorectomy. Menopause, 16(1), 15–23. https://doi.org/10.1097/gme.0b013e31818888f7
Toronto MIGS. (2024). Bladder function after surgery. https://www.torontomigs.com/bladder-function-after-surgery
TransHealthCare. (2024). The WPATH Standards of Care for gender-affirming surgery. https://www.transhealthcare.org/resources/wpath-standards-of-care-requirements-for-gender-affirming-surgery/
TransHub. (2023). Hysterectomy. https://www.transhub.org.au/clinicians/hysterectomy/
UCSF Transgender Care. (2023). Hysterectomy. https://transcare.ucsf.edu/guidelines/hysterectomy
University of Utah Health. (2024). Gender-affirming gynecologic surgeries. https://healthcare.utah.edu/transgender-health/gender-affirmation-surgery/gynecologic
Kho, R. M., & Abrao, M. S. (2012). Ovarian remnant syndrome: Etiology, diagnosis, treatment and impact of endometriosis. Current Opinion in Obstetrics and Gynecology, 24(4), 210–214. https://doi.org/10.1097/GCO.0b013e3283558539